Reported 2 days ago
GoodRx Holdings has partnered with Novo Nordisk to offer Ozempic and Wegovy pens for $499 per month to eligible self-paying patients, significantly lowering costs for these popular GLP-1 medications. This initiative aims to improve access for those without insurance coverage, responding to a rising demand as many seek affordable treatments for weight loss. Following this announcement, GoodRx's stock has surged by over 30%.
Source: YAHOO